BioCentury | Apr 15, 2013
Company News

National Patent Development Corp., PolyMasc deal

...NPD’s Hydro Med Sciences division (New Brunswick, N.J.) and PolyMASC extended their June 1996 agreement, in...
...1996 agreement, in which they are applying Hydro Med’s hydrogel parenteral drug delivery implant and PolyMASC’s...
...production of devices for in vivo testing. National Patent Development Corp. (NPD), New York, N.Y. PolyMASC Pharmaceuticals plc...
BioCentury | Aug 25, 2008
Company News

Lipoxen management update

...Lipoxen plc (LSE:LPX), London, U.K. Business: Drug delivery Hired: Ajay Agrawal, founder of polyMASC Pharmaceuticals plc (now part...
BioCentury | Jul 14, 2003
Company News

Valentis, J&J supply/service news

...VLTS's PolyMasc Pharmaceuticals Inc. subsidiary and JNJ's Alza Corp. subsidiary settled their ongoing patent infringement litigation...
...The settlement also ends the companies' patent opposition proceedings in Japan and Europe. As settled, PolyMasc...
BioCentury | May 5, 2003
Product Development

The EPO crowd in Europe

...is to develop a second-generation pegylated version of EPO using technology it has licensed from PolyMasc Pharmaceuticals plc...
BioCentury | Feb 17, 2003
Company News

Prolong Pharmaceuticals Inc., Valentis deal

...cash payment, and is eligible for milestones and royalties. OptiPEG was developed by VLTSD subsidiary PolyMasc Pharmaceuticals plc...
BioCentury | Feb 17, 2003
Product Development

Prolong: Putting the PEG in biogenerics

...immunogenicity and side effects. To that end, Prolong last week licensed OptiPEG pegylation technology from PolyMasc Pharmaceuticals plc...
...NKTR settled pegylation-related litigation in 2002 with a cross-licensing agreement (see BioCentury, Jan. 14, 2002). PolyMasc...
...a subsidiary of Valentis Inc. (VLTSD, Burlingame, Calif.), provides an alternative route, according to Abuchowski. "PolyMasc's...
BioCentury | Feb 10, 2003
Company News

Valentis, Prolong PEG licensing deal

...cash payment, and is eligible for milestones and royalties. OptiPEG was developed by VLTSD subsidiary PolyMasc...
BioCentury | Feb 10, 2003
Company News

Valentis, J&J supply/service news

...dismissed a demand for invalidation of claim five in Japanese Patent No. 2948246 owned by PolyMasc...
...Patent Office's Opposition Division had found in favor of PolyMasc's patent in a prior proceeding. PolyMasc...
BioCentury | Dec 9, 2002
Company News

Valentis, J&J cancer news

...No. 6,132,763 covering PEGylated liposomes assigned to PolyMasc, a wholly-owned subsidiary of VLTS. In 2001, PolyMasc...
BioCentury | May 6, 2002
Company News

Proteome Sciences management update

...Proteomics Hired: James Green as business development director, formerly commercial director at Valentis Inc. 's PolyMasc Pharmaceuticals plc...
Items per page:
1 - 10 of 44
BioCentury | Apr 15, 2013
Company News

National Patent Development Corp., PolyMasc deal

...NPD’s Hydro Med Sciences division (New Brunswick, N.J.) and PolyMASC extended their June 1996 agreement, in...
...1996 agreement, in which they are applying Hydro Med’s hydrogel parenteral drug delivery implant and PolyMASC’s...
...production of devices for in vivo testing. National Patent Development Corp. (NPD), New York, N.Y. PolyMASC Pharmaceuticals plc...
BioCentury | Aug 25, 2008
Company News

Lipoxen management update

...Lipoxen plc (LSE:LPX), London, U.K. Business: Drug delivery Hired: Ajay Agrawal, founder of polyMASC Pharmaceuticals plc (now part...
BioCentury | Jul 14, 2003
Company News

Valentis, J&J supply/service news

...VLTS's PolyMasc Pharmaceuticals Inc. subsidiary and JNJ's Alza Corp. subsidiary settled their ongoing patent infringement litigation...
...The settlement also ends the companies' patent opposition proceedings in Japan and Europe. As settled, PolyMasc...
BioCentury | May 5, 2003
Product Development

The EPO crowd in Europe

...is to develop a second-generation pegylated version of EPO using technology it has licensed from PolyMasc Pharmaceuticals plc...
BioCentury | Feb 17, 2003
Company News

Prolong Pharmaceuticals Inc., Valentis deal

...cash payment, and is eligible for milestones and royalties. OptiPEG was developed by VLTSD subsidiary PolyMasc Pharmaceuticals plc...
BioCentury | Feb 17, 2003
Product Development

Prolong: Putting the PEG in biogenerics

...immunogenicity and side effects. To that end, Prolong last week licensed OptiPEG pegylation technology from PolyMasc Pharmaceuticals plc...
...NKTR settled pegylation-related litigation in 2002 with a cross-licensing agreement (see BioCentury, Jan. 14, 2002). PolyMasc...
...a subsidiary of Valentis Inc. (VLTSD, Burlingame, Calif.), provides an alternative route, according to Abuchowski. "PolyMasc's...
BioCentury | Feb 10, 2003
Company News

Valentis, Prolong PEG licensing deal

...cash payment, and is eligible for milestones and royalties. OptiPEG was developed by VLTSD subsidiary PolyMasc...
BioCentury | Feb 10, 2003
Company News

Valentis, J&J supply/service news

...dismissed a demand for invalidation of claim five in Japanese Patent No. 2948246 owned by PolyMasc...
...Patent Office's Opposition Division had found in favor of PolyMasc's patent in a prior proceeding. PolyMasc...
BioCentury | Dec 9, 2002
Company News

Valentis, J&J cancer news

...No. 6,132,763 covering PEGylated liposomes assigned to PolyMasc, a wholly-owned subsidiary of VLTS. In 2001, PolyMasc...
BioCentury | May 6, 2002
Company News

Proteome Sciences management update

...Proteomics Hired: James Green as business development director, formerly commercial director at Valentis Inc. 's PolyMasc Pharmaceuticals plc...
Items per page:
1 - 10 of 44